Autolus Therapeutics plc announced that Dr. Robert Iannone, Executive Vice President, Global Head of Research & Development of Jazz Pharmaceuticals plc, has been appointed as a non-executive director to Autolus' board of directors, effective as of June 15, 2023. Dr. Iannone will serve as a Class I Director, with an initial term expiring at Autolus' 2025 Annual General Meeting. Dr. Iannone brings to Autolus a wealth of experience in the life science industry, having worked across a broad range of therapeutic areas and phases of development, including immuno-oncology programs at Jazz Pharmaceuticals plc, Immunomedics Inc., AstraZeneca plc and Merck & Co.

Inc. Prior to joining Jazz Pharmaceuticals, Dr. Iannone served as Head of Research and Development and Chief Medical Officer of Immunomedics Inc. He previously served as Senior Vice President and Head of Immuno-oncology, Global Medicines Development, and the Global Products Vice President at AstraZeneca plc and held several management roles at Merck & Co. Inc., culminating in his role as Executive Director and Section Head of Oncology Clinical Development. Prior to then, Dr. Iannone served as Assistant Professor of Pediatrics at the University of Pennsylvania School of Medicine.

Dr. Iannone has also held senior governance and government health advisory roles. He currently serves on the Board of Directors of iTeos Therapeutics and previously served on the Board of Directors of Jounce Therapeutics. He has served on the Cancer Steering Committee of the Biomarkers Consortium/Foundation for the National Institutes of Health since 2011, and currently sits on the executive committee of Biomarkers Consortium.

Dr. Iannone received an M.D. from Yale University and an M.S.C.E. from University of Pennsylvania. He completed his Residency and Chief Residency in Pediatrics and a Fellowship in Pediatric Hematology-Oncology at Johns Hopkins University.